Search PubMed⌕ Search

Biomedical subjects

R G Masters

Publications and source records attributed to R G Masters.

At least 37 records · Page 2Linked to original sources

Cardiac transplantation after mechanical circulatory support: a Canadian perspective.

BACKGROUND: To assess the relative efficacy of cardiac transplantation after mechanical circulatory support with a variety of support systems, we analyzed our consecutive series of patients who had and did not have mechanical support before transplantation. METHODS: A review of 209 patients undergoing cardiac transplantation from 1984 to May 1995 was performed. Group 1 consisted of 110 patients who were maintained on oral medications while awaiting transplantation, and group 2 consisted of 60 patients who required intravenous inotropic support. Group 3 included 39 patients who had transplantation after mechanical circulatory support for cardiogenic shock. The indication for device implantation was acute onset of cardiogenic shock in 38 patients and deterioration while awaiting transplantation in 1 patient. The support systems were an intraaortic balloon pump in 13 (subgroup 3A), a ventricular assist device in 7 (subgroup 3B), and a total artificial heart in 19 patients (subgroup 3C). RESULTS: After transplantation, infection was more common in group 3 (56%) than in group 1 (28%) or group 2 (32%) (p = 0.005). Survival to discharge was lower for group 3 (71.7%) than for group 1 (90.9%) or 2 (88.3%) (p = 0.009). For mechanically supported patients, survival to discharge was 84.6% in subgroup 3A, 71.4% in subgroup 3B, and 63.1% in subgroup 3C (p = not significant). CONCLUSIONS: Transplantation after mechanical support offers acceptable results in this group of patients for whom the only alternative is certain death. Patient selection and perioperative management remain the challenge to improving these results.

Administration, Oral↗

A remotely controlled and powered artificial heart pump.

An intrathoracic pulsatile artificial heart pump has been developed. Transcutaneous energy transfer and biotelemetry systems provide continuous power and remote monitoring and control, with no percutaneous connections required. The electrohydraulic system can be used either as a ventricular assist device or with modifications as a total artificial heart. The device uses a unidirectional axial flow pump coupled with a pressure activated one-way valve to allow hydraulic fluid to passively return to the volume displacement chamber during diastole. The transcutaneous energy transfer system provides power to the device and recharges the implantable battery pack. A wearable external controller and external battery pack provide the patient enhanced mobility and thus an improved quality of life. The biotelemetry system allows control and monitoring of the device after implantation, as well as an added capability to monitor and control the device remotely over public communication lines. Early prototypes have functioned failure free for up to 3 years in vitro. The device has sustained circulation in vivo for up to 4 days. Design optimization is continuing, and chronic in vivo evaluation is planned.

Animals↗

Bacterial pericarditis after heart transplantation: successful management of two cases with catheter drainage and antibiotics.

OBJECTIVE: To describe the diagnosis and management of bacterial pericarditis after heart transplantation. PATIENTS AND METHODS: Two patients with Staphylococcus aureus pericarditis after heart transplantation were successfully treated conservatively with closed catheter drainage and antibiotics. RESULTS: The patients were alive three and six years, respectively, following surgery. At follow-up, right heart catheterization demonstrated normal hemodynamics in one patient and a pattern of constrictive pericarditis in the other patient which was man-aged with furosemide. CONCLUSIONS: Conservative management of bacterial pericarditis by closed catheter drainage and antibiotics can be considered in selected patients after heart transplantation.

Adult↗

Determinants of hospital survival after cardiac transplantation.

To identify the preoperative factors that influence hospital survival after transplantation we analyzed our consecutive experience of 183 transplantations in 179 patients over a 10-year period. There were 151 male and 29 female transplant recipients ranging in age from 10 days to 70 years (mean, 48 +/- 1 years). Diagnoses included coronary disease in 110 patients, cardiomyopathy in 55 patients, valvular disease in 6 patients, and congenital heart disease in 9 patients. Seventy-seven had undergone a previous cardiac operation, and 30 patients required preoperative mechanical support. Forty patients received hearts from donors who were 40 years old or older (range, 40 to 62 years). Ischemic time was greater than 240 minutes in 32 cases, and pulmonary vascular resistance was greater than 3 Wood units in 40 patients (range, 3.1 to 10.0 Wood units). Cyclosporine induction was used in 52 patients, whereas 128 recipients received polyclonal antibody prophylaxis. There were 25 hospital deaths. Recipient diagnosis, use of mechanical support, donor age, and the immune suppression protocol were related to hospital survival according to univariate analysis. Using multiple logistic regression, only the method of immune suppression induction and the use of mechanical assists were significant independent determinants of survival. In conclusion, we believe that extended ischemic times and donor age do not adversely affect the early success of transplantation, whereas induction with immune globulin may reduce early mortality. Patients requiring mechanical support before transplantation continue to be a challenge.

Adolescent↗

Long-term experience with the Ionescu-Shiley pericardial valve.

To determine the long-term durability of the Ionescu-Shiley valve, we analyzed our experience with this valve at the University of Ottawa Heart Institute. To 1988, 780 patients have had aortic valve replacement (AVR = 528) or mitral valve replacement (MVR = 252). Of the aortic valves, 310 were standard profile and 218 were low profile. Of the mitral valves, 143 were standard profile and 109 were low profile. Actuarial survival at 10 years was as follows: AVR, 62% +/- 3%; MVR, 58% +/- 4%; p = 0.42. At 14 years, the results were AVR, 44% +/- 1% and MVR, 46% +/- 5%; p = 0.40. Reoperation was required in 197 patients. Structural failure was present in 85% of these valves, with leaflet tears alone in 69%, tears with calcification in 21%, and calcification alone in 10%. Leaflet tears occurred in 95% after AVR and in 78% after MVR (p = 0.006) and were seen in 95% of low-profile valves and 87% of standard-profile valves (p = 0.16). The actuarial freedom from reoperation at 10 years was: AVR, 58% +/- 3%; MVR, 62% +/- 5%; p = 0.49. At 13 years, these rates were 38% +/- 4% for AVR and 25% +/- 9% for MVR (p = 0.79). For AVR, the 10-year rate of freedom from reoperation was 57% +/- 4% for standard-profile valves and 57% +/- 8% for low-profile valves (p = 1.0). Similarly for MVR, the 10-year freedom from reoperation was 61% +/- 6% for standard-profile valves and 68% +/- 8% for low-profile valves.(ABSTRACT TRUNCATED AT 250 WORDS)

Actuarial Analysis↗

Comparative results with the St. Jude Medical and Medtronic Hall mechanical valves.

This study compared the clinical performance of the St. Jude Medical and Medtronic Hall mechanical valves in isolated aortic or mitral valve replacement. From 1984 to 1993, 349 St. Jude Medical valves (aortic 237, mitral 112) and 465 Medtronic Hall valves (aortic 272, mitral 193) were implanted in 814 patients at the University of Ottawa Heart Institute. The patients had similar preoperative characteristics. The hospital mortality rate for aortic valve replacement was 3.4% with the St. Jude Medical valve and 5.8% with the Medtronic Hall valve (p = 0.26) and the rate for mitral valve replacement was 8.9% with the St. Jude Medical valve and 11.9% with the Medtronic Hall valve (p = 0.54). Actuarial estimates of survival and freedom from complications were calculated. At 5 years the actuarial probability of survival (including hospital deaths) for aortic valve replacement was 86% +/- 3% with the St. Jude Medical valve and 68% +/- 4% with the Medtronic Hall valve (p = 0.0001) and for mitral valve replacement was 75% +/- 7% with the St. Jude Medical valve and 70% +/- 4% with the Medtronic Hall valve (p = 0.54). The most common cause of late death was cardiac failure and no deaths were caused by structural failure. The 5-year probability of freedom from bleeding after aortic valve replacement was 99% +/- 1% with the St. Jude Medical valve and 95% +/- 2% with the Medtronic Hall valve (p = 0.06) and after mitral valve replacement 99% +/- 1% with the St. Jude Medical valve and 97% +/- 2% with the Medtronic Hall valve (p = 0.37). The 5-year probability of freedom from thromboembolism after aortic valve replacement was 88% +/- 4% with the St. Jude Medical valve and 81% +/- 3% with the Medtronic Hall valve (p = 0.08) and after mitral valve replacement was 85% +/- 7% with the St. Jude Medical valve and 77% +/- 5% with the Medtronic Hall valve (p = 0.17). Reoperation was uncommon and there were no cases of structural valve failure. The 5-year actuarial estimate of freedom from reoperation therefore for aortic valve replacement was 99% +/- 1% with the St. Jude Medical valve and 96% +/- 2% with the Medtronic Hall valve (p = 0.09) and for mitral valve replacement was 98% +/- 2% with the St. Jude Medical valve and 95% +/- 3% with the Medtronic Hall valve (p = 0.40).(ABSTRACT TRUNCATED AT 400 WORDS)

Actuarial Analysis↗

Angiographic underestimation of coronary artery disease in a cardiac transplant donor.

There has been a great deal of attention given to the development of post-transplant arteriopathy in the cardiac transplant patient. Preexisting donor heart disease may be of equal importance in the development of allograft failure due to ischemia. The case of a 64-year-old female who received the heart of a 52-year-old female is reported. Death of the recipient occurred due to intraoperative complications. Despite normal pretransplant coronary angiography, autopsy found severe atherosclerotic coronary artery disease in the donor heart. This case report illustrates some of the limitations of angiography in the detection of coronary artery lesions in donor hearts.

Coronary Angiography↗

Assessment of the cytotoxicity of the photosensitizing drug BPD verteporfin using human vascular smooth muscle cells in culture.

Photosensitizing drugs are selectively taken up by lipid-rich lesions such as atheromatous plaque which when exposed to light render the drugs cytotoxic. However, skin photosensitivity which persists for many weeks is a significant side effect. We investigated the cytotoxicity of a new photosensitizing drug, the benzoporphyrin derivative BPD verteporfin (Quadra Logic Technologies), which does not have this deleterious side effect. Vascular smooth muscle cells (VSMC) from normal human mammary and diseased human coronary arteries were grown in culture from explants and characterized with respect to their growth rates. The sensitivity to BPD with and without light was assessed by measuring viability after treatment. The lethal dose of drug for 50% viability loss (LD50) for BPD with light was approximately 12.5 ng/ml for mammary artery, with 52 +/- 8% cell survival (n = 6). The coronary artery VSMC from all patient sources, although differing significantly in growth rate, had a survival of 44 +/- 6% (n = 12) at the same concentration of BPD used for the mammary artery SMC (p = NS). Our results established the LD50 for BPD using human arterial sources of SMC and showed that the growth rates of the cells did not affect the cytotoxicity of the drug.

Cell Survival↗

Is there a place for cold crystalloid cardioplegia in the 1990s?

New cardioplegic techniques have been advocated as advantageous when compared with previously accepted standard methods. This study assessed results of a recent cohort of 388 consecutive patients undergoing coronary artery bypass grafting between 1990 and 1992 using a standard cold crystalloid cardioplegia. The mean age of patients was 61.0 +/- 0.5 years; there were 324 male and 64 female patients. Risk factor distribution has not changed recently. Preoperative left ventricular dysfunction (grade III/IV) was significant in 35.1% of patients, and 63.3% had previous myocardial infarctions. Intraoperative cardiac arrest was achieved using an average of 1,254 +/- 14 mL of St. Thomas' solution in multiple doses. Patients had a mean of 3.1 +/- 0.04 grafts constructed, with 87.7% receiving at least one internal thoracic artery graft. Anoxia and total cardiopulmonary bypass times were 40.6 +/- 0.6 and 90.3 +/- 1.4 minutes, respectively. Perioperative myocardial infarction was identified in 5.7% of patients with elevated creatine kinase levels and electrocardiographic measurement changes, inotropic agents were required in 17.8%, and the intraaortic balloon was required in 3.6% of patients. Hospital stays averaged 11.2 +/- 0.5 days. Overall 30-day mortality was 1.0%, whereas those patients undergoing elective operation (n = 219) had a mortality of 0%. In conclusion, cold crystalloid cardioplegia has the advantages of being inexpensive and simple to use. These results suggest that coronary artery bypass grafting still may be performed very safely using this technique.

Bicarbonates↗

Retrograde dislodgement of a Harken mitral valve disc occluder.

The previous generation of mechanical heart valves was unfortunately prone to disc variance, dislodgement and catastrophic failure. This is illustrated by the recent case of a 59-year-old male who presented with retrograde dislodgement of a Harken mitral valve disc 20 years after implantation. Expediency in diagnosis and implementing surgical therapy are the keys to success in these patients.

Echocardiography↗

Transcutaneous energy transfer system performance evaluation.

A transcutaneous energy transfer (TET) system has been developed to power implantable devices such as artificial hearts, defibrillators, and electrical stimulators. Transcutaneous coupling of power to these implanted devices remains a favorable alternative as percutaneous lines are avoided in order to eliminate the potential of infection and allow patient mobility. In vitro, in vivo, ex vivo, and human cadaver studies of the electrohydraulic ventricular assist device TET have demonstrated that power can be transmitted over a range of skin thicknesses of 3-15 mm and can tolerate radial misalignments of up to 20 mm. Sensitivity to coil separation and radial misalignment variations has been addressed by the development of an auto-tuning TET. The system has only a 10% attenuation in secondary coil voltage when metallic objects are in contact with the primary coil. The system has demonstrated a power transfer efficiency of 60-80% for power demands from 5 to 70 W. The TET secondary coil will provide an output voltage of 10-25 V for current demands from 0.5 to 4.0 A. TET chronic studies in porcine models have demonstrated no adverse effect to the tissue when up to 40 W of power can be delivered to an implanted load without the tissue-contacting surface of the coil exceeding 42 degrees C. In conclusion, the TET is a feasible alternative for tether-free power transmission.

Cadaver↗

Aortic valve replacement within a composite graft.

Failure of a bioprosthetic valve within a composite graft presents a challenging surgical problem. A solution to this, as described here, involves leaving a remnant of the failed valve intact within the graft. This forms the annulus to which the new valve is sewn, thus simplifying the operation.

Aortic Valve↗

Neuroendocrine response to cardiac transplantation.

OBJECTIVE: The neuroendocrine response to heart transplantation was characterized in 11 patients with special reference to long term effects on plasma hormone concentration. DESIGN: Multiple serial measurements of preload, ejection fraction, plasma renin activity (PRA), aldosterone, atrial natriuretic factor (ANF) and catecholamines were made over time. SETTING: Tertiary care cardiac referral, university-based centre. PATIENTS: Eleven adult patients undergoing orthotopic cardiac transplantation were studied. The group consisted of 10 males and one female (mean age 52 +/- 2 years). Eight patients had coronary atherosclerosis, two had idiopathic cardiomyopathy and one had valvular heart disease. All patients were in end-stage heart failure (Canadian Cardiovascular Society class IV) and two also had angina. INTERVENTIONS: Right heart catheterization and hormonal assays in blood were performed simultaneously preoperatively and postoperatively at 24 h, 48 h and during each endomyocardial biopsy. An endomyocardial biopsy to detect rejection was performed weekly for two to four weeks, then every three to four months at one year postoperatively. Hemodynamic measurements included central venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP). Ejection fraction was measured in each patient using radionuclide ventriculography preoperatively and serially through the postoperative period. MAIN RESULTS: Following transplantation, transient elevation of intracardiac filling pressures occurred. The CVP and PCWP were elevated at 15 +/- 2 and 17 +/- 1 mmHg, respectively, early postoperatively (ie, days 2 to 30 postsurgery). Late postoperatively (ie, more than 30 days postoperatively), the CVP and PCWP decreased to 8 +/- 1 and 12 +/- 1 mmHg, respectively. Systolic function, as measured by radionuclide ejection fraction, did not change significantly from the early to the late postoperative period (60 +/- 5% early versus 59 +/- 2% late postoperatively). PRA and plasma aldosterone fell in association with the decrease in filling pressures (PRA was 2.4 +/- 0.8 ng/mL/h early versus 1.0 +/- 0.2 ng/ml/h late; plasma aldosterone was 122 +/- 31 pg/mL early versus 103 +/- 16 pg/mL late). Plasma aldosterone levels were similar in the early and late postoperative periods, except during the first day after surgery during which a transient elevation occurred. ANF remained markedly elevated despite the fall in filling pressures (323 +/- 50 pg/mL preoperatively, 360 +/- 33 pg/mL early postoperatively and 322 +/- 31 pg/mL late postoperatively). CONCLUSIONS: The authors conclude that transient cardiac dysfunction occurs following cardiac transplantation with elevation of filling pressures and continued increased activity of the renin-angiotensin-aldosterone system (RAAS) and elevated plasma ANF levels. With return of cardiac function and normalization of filling pressures, the activity levels of the RAAS decrease, but not those of ANF, which remain chronically abnormally elevated. It is not clear whether this persistent elevation of ANF is the result of factors related to the transplant procedure, such as extrinsic denervation or antirejection therapy, among others, or is the persistence of factors acting preoperatively. However, known interactions of cyclosporine with vascular smooth muscle and endothelial cells leading to increased sensitivity to vasopressor hormones and increased circulating levels of endothelin appear as the most likely explanation for the chronic elevation of ANF plasma levels. In this context, ANF may play a key role in moderating the side effects of cyclosporine treatment.

Aldosterone↗

Paradoxical embolism-in-transit: diagnosis and surgical treatment.

Paradoxical embolism-in-transit is an uncommon presentation of the thromboembolism complex. The advent of echocardiography has permitted its antemortem diagnosis and serves to guide treatment; this is illustrated by the case of a 51-year-old female who presented with paradoxical embolism-in-transit and pulmonary embolism following craniotomy. Echocardiography demonstrated mobile clot straddling the atrial septum and embolus in the right pulmonary artery. Surgery successfully removed all clots as demonstrated by intraoperative echocardiography, and the patient had an uneventful recovery.

Craniotomy↗

Critical anatomic dimensions for intrathoracic circulatory assist devices.

The design of totally implantable circulatory support devices must account for the anatomical constraints of the body cavity. To aid development of an implantable electrohydraulic ventricular assist device (EVAD), thoracic anatomical measurements and fit trials were performed. Various dimensions of the thoracic cavity were measured in 19 preserved and fresh cadavers. The mean left ventricle apex to chest wall distance was 2.7 +/- 0.2 cm. The mean sagittal radius of curvature at the fifth rib was 11.1 +/- 0.4 cm, and the transverse radius at the fifth rib was 9.4 +/- 0.3 cm. The mean sternal length was 18.9 +/- 1.2 cm. Using these measurements a model measuring 17.5 x 10.5 x 3.8 cm was designed. This model was placed in the chest of 11 patients undergoing open heart surgery. In one patient there was significant lung compression and in another hypotension suggesting great vessel compression. Finally, 1 of 11 patients had a short sternum and a small thorax, and the device did not fit. In conclusion, thoracic measurements may be used in the design of circulatory support devices. The model fit adequately in 73% of patient trials.

Adult↗

Mechanical bridge to cardiac transplant: where do we stand in 1990?

Various mechanical devices have been used to support the circulation in patients requiring cardiac transplantation who are in cardiogenic shock. The devices produce either a pulsatile or nonpulsatile blood-flow pattern. Of the former, the intra-aortic balloon pump is the most frequently used. However, it augments but does not replace the function of the left ventricle. At the Ottawa Heart Institute, orthotopic replacement of both ventricles with a total artificial heart has proven a reliable and effective bridge to transplantation in selected patients. Heterotopic ventricles, known as ventricular assist devices, may also be used to replace the function of one or both ventricles and are increasingly being used to maintain the circulation. The future of nonpulsatile devices for mechanical support remains unclear because the long-term effects of this unphysiologic flow pattern are unknown. As refinements in circulatory support devices continue and as patient selection and timing of device insertion become more clearly defined, the results in these patients will likely approach those of elective cardiac transplantation.

Assisted Circulation↗

Long-term clinical results with the Ionescu-Shiley pericardial xenograft.

From 1977 to 1987, 829 Ionescu-Shiley pericardial valves (Shiley, Inc., Irvine, Calif.) were implanted in 766 patients at the University of Ottawa Heart Institute. There were 476 patients who had aortic valve replacement, 234 who had mitral valve replacement, and 44 who had double valve replacement. The standard-profile design was used in 508 patients and the low-profile design in 321 patients. Follow-up was obtained for 97% of patients, with calculation of event-free probabilities. At 10 years the overall probability of freedom from structural failure was 48% +/- 7% after aortic valve replacement, 44% +/- 15% after mitral valve replacement, and 79% +/- 11% after double valve replacement. Although at 5 years the probability of failure was statistically lower with the low-profile design, this favorability was lost by 6 years. Freedom from structural failure was only 47% +/- 7% for the standard-profile valve at 10 years. Thus the probability of freedom from reoperation was only 46% +/- 7% after aortic valve replacement, 39% +/- 6% after mitral valve replacement, and 65% +/- 20% after double valve replacement at 10 years. Thromboembolism occurred in 69 patients, for a predicted freedom from this complication at 10 years of 79% +/- 3% after aortic, 73% +/- 7% after mitral, and 96% +/- 4% after double valve replacement. There were 31 cases of endocarditis. The 10-year predicted freedom from endocarditis, therefore, was 86% +/- 3% after aortic, 98% +/- 1% after mitral, and 97% +/- 1% after double valve replacement. A total of 221 operative and late deaths were recorded in this series. Prosthetic valve failure accounted for 27% of late deaths. The 10-year survival rates were estimated to be 56% +/- 5% (aortic valve replacement), 54% +/- 6% (mitral valve replacement), and 51% +/- 8% (double valve replacement). We concluded that the Ionescu-Shiley pericardial xenograft provides less than optimal clinical performance and its use has been discontinued.

Actuarial Analysis↗